Last Update 18 Apr 26

ELMD: Refined Discount Rate And P/E Assumptions Will Drive Future Upside

Analysts raised their price target on Electromed by $2, reflecting updated assumptions about the discount rate, profit margin, revenue growth, and future P/E that support a slightly higher valuation framework.

Analyst Commentary

Bullish Takeaways

Bullish analysts see the higher price target as consistent with refreshed assumptions on discount rate and future P/E that leave room for upside if execution stays on track.
Updated margin assumptions suggest potential for better profitability, which supports a richer valuation framework in their models.
Revised revenue growth expectations are factored into the new target, with analysts indicating that the company’s current trajectory justifies a modestly higher multiple.
The combination of adjusted profit margin and P/E inputs is viewed as constructive for risk and reward, as long as the company can deliver against these embedded forecasts.

Bearish Takeaways

Bearish analysts highlight that the increase in the price target is incremental, which they see as a signal that upside may be more measured from here.
There is caution that the updated valuation leans on specific assumptions around discount rate and margins, which could be sensitive to changes in operating or macro conditions.
Some analysts flag the reliance on future P/E assumptions, noting that any shortfall in earnings delivery could pressure the current valuation framework.
The revised revenue growth expectations, while supportive of a higher target, leave less room for error if execution on sales and profitability does not align with forecasts.

What's in the News

From October 1, 2025 to December 31, 2025, Electromed repurchased 105,593 shares for US$2.76 million, equal to 1.26% of shares referenced in the announcement (Key Developments).
Across the full authorization announced on September 9, 2025, the company completed the repurchase of 146,441 shares for US$3.77 million, representing 1.75% of the referenced share base (Key Developments).
The 2025 repurchases, now completed, indicate that the company has executed the buyback program as outlined in the September 9, 2025 announcement (Key Developments).

Valuation Changes

$ Fair Value: unchanged at $37.0, indicating no shift in the central valuation estimate used in the models.
Discount Rate: increased slightly from 7.75% to 7.78%, a modest adjustment that can trim the present value of future cash flows in the models.
Revenue Growth: kept effectively stable at about 10.70%, suggesting no material change to top line expectations in the updated assumptions.
Net Profit Margin: maintained at roughly 15.37%, with only a very small numerical adjustment that does not signal a different profitability view.
Future P/E: nudged higher from 22.57x to 22.59x, a minor change that still supports the slightly higher price target underpinning the latest analyst work.

3 views

Key Takeaways

Increased awareness and industry campaigns are expected to boost diagnosis and treatment rates, driving sustained growth and expanded market share.
Digital investments, expanded sales force, and operational improvements will enhance productivity, margins, and efficiency, supporting ongoing revenue and earnings growth.
Heavy reliance on the U.S. market, single product concentration, and rising cost pressures expose Electromed to significant risks from reimbursement changes and execution challenges on growth initiatives.

Catalysts

About Electromed

Develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally.What are the underlying business or industry changes driving this perspective?

Heightened clinical and patient awareness around bronchiectasis, accelerated by new therapies and market development campaigns (such as Electromed's "Triple Down on Bronchiectasis" and broader industry education), is likely to increase both diagnosis and treatment rates among the large underpenetrated and undiagnosed patient pool; this should drive sustained revenue growth over several years.
Early adoption trends for preventative, home-based airway management solutions-supported by shifting referral patterns and a healthcare system increasingly oriented towards value-based, at-home care-continue to underpin expansion in Electromed's Core Home Care segment, supporting recurring revenue growth and elevated gross margins.
Expansion of the direct sales force, coupled with investments in digital tools like the new CRM system and e-prescribing solutions, has led to meaningfully improved sales productivity per representative; continuing these initiatives is expected to deliver higher revenue per rep and overall top-line growth.
Ongoing operational optimizations-including manufacturing footprint expansion and process improvements-will provide capacity for multi-year volume growth, allowing the company to scale efficiently while protecting high gross margins and enhancing operating leverage, thus improving net earnings.
Market share gains in hospital and DME channels, catalyzed by strategic team expansion and competitor disruption, present Electromed with new avenues for incremental revenues, and establish additional entry points for future Home Care conversions, positively impacting both total revenue and profitability.

Electromed Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Electromed's revenue will grow by 10.7% annually over the next 3 years.
Analysts assume that profit margins will increase from 13.1% today to 15.4% in 3 years time.
Analysts expect earnings to reach $14.4 million (and earnings per share of $1.53) by about April 2029, up from $9.0 million today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 25.7x on those 2029 earnings, up from 24.0x today. This future PE is lower than the current PE for the US Medical Equipment industry at 26.0x.
Analysts expect the number of shares outstanding to decline by 1.32% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.78%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Electromed's heavy reliance on the domestic U.S. market (99% of revenues) and limited international presence leaves the company vulnerable to potential shifts in U.S. healthcare reimbursement policies or demand cycles, which could negatively impact future revenue growth.
The business remains highly concentrated around the SmartVest platform, making Electromed susceptible to revenue and earnings risks if a disruptive competing device or alternative therapy (including new drug regimens for bronchiectasis or digital health solutions) gains strong traction and takes market share.
Sustained gross margin performance is partly attributable to favorable payer mix and a strong Home Care segment, but ongoing healthcare cost containment pressures from payers and the potential for reduced reimbursement rates may erode profitability and compress net margins over time.
Margin expansion from manufacturing optimization is expected to be offset by wage inflation and possible tariff impacts through upstream suppliers, while talent or supply chain shortages could further raise costs and disrupt production, adversely affecting margins and earnings.
The company's recent and future growth initiatives (e.g., sales force expansion, new CRM implementation, direct-to-patient marketing) increase SG&A expenses and introduce execution risk, such that failure to convert these investments into sustained revenue and earnings growth could pressure financial performance.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $37.0 for Electromed based on their expectations of its future earnings growth, profit margins and other risk factors.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $93.4 million, earnings will come to $14.4 million, and it would be trading on a PE ratio of 25.7x, assuming you use a discount rate of 7.8%.
Given the current share price of $26.06, the analyst price target of $37.0 is 29.6% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Electromed?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Bronchiectasis Awareness And Home Care Will Drive Lasting Success